[EN] HALOETHYL UREA COMPOUNDS AND THEIR USE TO ATTENUATE, INHIBIT OR PREVENT NON-CANCEROUS PATHOGENIC CELLULAR PROLIFERATION AND DISEASES ASSOCIATED THEREWITH<br/>[FR] COMPOSES D'UREE HALOETHYLE ET LEUR UTILISATION EN VUE D'ATTENUER, D'INHIBER OU DE PREVENIR LA PROLIFERATION CELLULAIRE PATHOGENE NON CANCEREUSE ET LES MALADIES Y ETANT ASSOCIEES
申请人:IMOTEP INC
公开号:WO2004106292A1
公开(公告)日:2004-12-09
The present invention provides haloethyl urea compounds as described in Formula (I) and their use as anti-proliferative agent in the attenuation, inhibition, or prevention of non-cancerous cellular proliferation. These compounds are also provided for use as a therapeutic agent in the treatment of a disease or disorder, wherein pathogenesis of said disease or disorder is associated with non-cancerous pathogenic cellular proliferation.
[EN] HALOETHYL UREA COMPOUNDS AND THE USE THEREOF TO ATTENUATE, INHIBIT OR PREVENT CANCER CELL MIGRATION<br/>[FR] COMPOSES D'UREE HALOETHYLE ET LEUR UTILISATION EN VUE D'ATTENUER, D'INHIBER OU DE PREVENIR LA MIGRATION DE CELLULES CANCEREUSES
申请人:IMOTEP INC
公开号:WO2004106291A1
公开(公告)日:2004-12-09
The present invention provides haloethyl urea compounds as described in Formula (I) and their use as therapeutic agent in the attenuation, inhibition, or prevention of cancer cell migration and cancer cell proliferation.
CELL-BASED VEHICLES FOR POTENTIATION OF VIRAL THERAPY
申请人:Calidi Biotherapeutics, Inc.
公开号:EP3801584A2
公开(公告)日:2021-04-14
ENHANCED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
申请人:Calidi Biotherapeutics, Inc.
公开号:EP3876951A1
公开(公告)日:2021-09-15
Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: Design, synthesis, molecular modeling, and preliminary biological evaluation
作者:Shirshendu DasGupta、Prashant R. Murumkar、Rajani Giridhar、Mange Ram Yadav
DOI:10.1016/j.bmc.2009.04.003
日期:2009.5
tetrahydropyrimidin-2(1H)-ones were synthesized and evaluated for their TACE inhibitory activity. Most of the compounds showed very good TACE inhibitory activity. Docking study clearly indicates importance of the P1′ group of the inhibitor for the TACE inhibitory activity. This work proves that these two classes of molecules could be used as potential leads for the development of TACE inhibitors.